Home › Free Stock Grades › AKTS
Aktis Oncology, Inc. (AKTS) Stock Grade
AKTS · Healthcare
A+
Market Cap
$1.2B
P/E Ratio
—
Revenue Growth (YoY)
+336.9%
Net Margin
-980.9%
Return on Equity
43.6%
Dividend Yield
None
About Aktis Oncology, Inc.'s fundamentals
Aktis Oncology is a biotechnology company with a market capitalization of $1.2 billion that demonstrated significant revenue growth of 336.9% year-over-year, indicating rapidly expanding commercial activity. However, the company reported a substantial net loss in its latest annual statement, reflected in a net margin of -980.9%, meaning it is currently unprofitable and losing approximately $9.81 for every dollar of revenue generated. The company does not pay a dividend and lacks a meaningful P/E ratio due to its negative earnings position.